Point-of-care anti-BCMA CAR T-cell therapy induces encouraging response rates in relapsed/ refractory multiple myeloma patients mostly with high-risk disease features
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2023）
关键词
refractory multiple myeloma patients,refractory multiple myeloma,multiple myeloma,point-of-care,anti-bcma,t-cell,high-risk
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要